Newsfeeds - Spark Newswire

2 minute read

Emergent BioSolutions Reports Initiation Of Pivotal Phase 3 Trial Evaluating Safety, Immunogenicity Of Its Chikungunya Vaccine Candidate, CHIKV VLP

Today, 2:23 PM

Emergent BioSolutions Inc. (NYSE:EBS) today announced the first participant dosed in its pivotal phase 3 study evaluating the safety and immunogenicity of the company’s investigational chikungunya virus (CHIKV)

EBS

2 minute read

News

5 Value Stocks To Watch In The Healthcare Sector

By Benzinga Insights

Today, 2:23 PM

The Meaning Behind Value Stocks

BXRX

5 minute read

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

By Shanthi Rexaline

Today, 2:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 30)

ADMA

7 minute read

The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug

By Shanthi Rexaline

Today, 2:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA Calendar Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28)

ABBV

5 minute read

The Daily Biotech Pulse: Eisai, Biogen Pursue Approval Of Second Alzheimer’s Treatment; Sanofi Changes mRNA Strategy; GSK Subsidiary To Develop Long-Acting HIV Preventive

By Shanthi Rexaline

Today, 2:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 27)

AFIB

6 minute read

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs

By Shanthi Rexaline

Today, 2:23 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 20)

ABEO

1 minute read

Emergent Secures Contract To Manufacture Providence Therapeutics’ COVID-19 Vaccine Candidate

By Vandana Singh

Today, 2:23 PM

Emergent BioSolutions Inc (NYSE:EBS) has signed a five-year agreement with Providence Therapeutics valued at about $90 million to develop and manufacture its COVID-19…

EBS

2 minute read

Emergent BioSolutions Secures Multi-Year Development And Manufacturing Agreement With Providence Therapeutics for Its mRNA COVID-19 Vaccine Candidate, PTX-COVID19-B

By Benzinga Newsdesk

Today, 2:23 PM

Total baseline value for Emergent is approximately $90 million USD, further expanding the collaboration between the companies, which began in February 2021 Emergent BioSolutions Inc. (NYSE:EBS)

EBS

2 minute read

Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns

By Shivdeep Dhaliwal

Today, 2:23 PM

More than a million doses of Moderna Inc’s (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia

EBS

1 minute read

Emergent BioSolutions’ COVID-19 Plasma Candidate To Be Tested As Outpatient Treatment

By Vandana Singh

Today, 2:23 PM

Emergent BioSolutions Inc (NYSE:EBS) has announced the initiation of a Phase 3 trial that will evaluate its investigational SARS-CoV-2 Immune Globulin…

EBS